T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Patterson-UTI
PTEN
$4.32B
| $2.07M | ﹤0.01% |
338,903
+31,983
| +10% | +$191K |
|
1727
Hawaiian Electric Industries
HE
$2.05B
| $2.06M | ﹤0.01% |
167,826
-4,986
| -3% | -$57.8K |
|
1728
RXO
RXO
$3.88B
| $2.06M | ﹤0.01% |
163,095
+20,893
| +15% | +$308K |
|
1729
Enerpac Tool Group
EPAC
$1.88B
| $2.06M | ﹤0.01% |
53,788
+1,086
| +2% | +$43K |
|
1730
Taboola.com
TBLA
$1.1B
| $2.06M | ﹤0.01% |
446,131
+144,631
| +48% | +$544K |
|
1731
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$23.3B
| $2.05M | ﹤0.01% |
38,814
| – | – |
|
1732
Voyager Therapeutics
VYGR
$197M
| $2.05M | ﹤0.01% |
521,651
-60,048
| -10% | -$266K |
|
1733
Par Pacific Holdings
PARR
$4.05B
| $2.04M | ﹤0.01% |
58,019
-50,211
| -46% | -$2M |
|
1734
Werner Enterprises
WERN
$2.32B
| $2.04M | ﹤0.01% |
67,824
+8,891
| +15% | +$244K |
|
1735
Century Aluminum
CENX
$4.69B
| $2.03M | ﹤0.01% |
51,725
+2,217
| +4% | +$69.3K |
|
1736
Choice Hotels
CHH
$4.71B
| $2.02M | ﹤0.01% |
21,146
+1,927
| +10% | +$183K |
|
1737
Walker & Dunlop
WD
$1.46B
| $2.02M | ﹤0.01% |
33,513
+3,574
| +12% | +$254K |
|
1738
Warner Music
WMG
$13.4B
| $2.01M | ﹤0.01% |
65,474
+3,300
| +5% | +$101K |
|
1739
Lionsgate Studios
LION
$3.59B
| $2.01M | ﹤0.01% |
219,926
+19,477
| +10% | +$139K |
|
1740
T. Rowe Price Floating Rate ETF
TFLR
$688M
| – | – |
0
| – | – |
|
1741
AtriCure
ATRC
$2.24B
| $2M | ﹤0.01% |
50,577
+2,121
| +4% | +$77.8K |
|
1742
Adeia
ADEA
$3.31B
| $1.99M | ﹤0.01% |
115,579
+4,565
| +4% | +$67.7K |
|
|
CIVI
1743
DELISTED
Civitas Resources
CIVI
| $1.99M | ﹤0.01% |
73,594
+3,336
| +5% | +$96.5K |
|
1744
Syndax Pharmaceuticals
SNDX
$1.72B
| $1.99M | ﹤0.01% |
94,829
+3,695
| +4% | +$64.5K |
|
1745
Enterprise Financial Services Corp
EFSC
$2.4B
| $1.99M | ﹤0.01% |
36,767
+2,689
| +8% | +$148K |
|
1746
Artivion
AORT
$1.4B
| $1.98M | ﹤0.01% |
43,322
+3,288
| +8% | +$146K |
|
1747
Alphatec Holdings
ATEC
$1.52B
| $1.97M | ﹤0.01% |
93,651
+6,654
| +8% | +$123K |
|
|
NSA
1748
DELISTED
National Storage Affiliates Trust
NSA
| $1.96M | ﹤0.01% |
69,488
+6,616
| +11% | +$197K |
|
1749
City Holding Co
CHCO
$2.08B
| $1.96M | ﹤0.01% |
16,422
+473
| +3% | +$57.5K |
|
1750
Fortrea Holdings
FTRE
$1.69B
| $1.95M | ﹤0.01% |
112,984
+20,514
| +22% | +$253K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.